The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Beyond Addiction: Medical Therapy for Addiction May Benefit Medical Adherence

Beyond Addiction: Medical Therapy for Addiction May Benefit Medical Adherence

June 17, 2019 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Dr. Stoller said all of these medications are underutilized, with buprenorphine the most studied in this regard. To dispense it, physicians need a waiver. “The studies all show the same thing,” he said. “The initial induction can be intimidating for people, because you can get precipitated withdrawal starting people on a partial agonist who are dependent on a full agonist. They’re also concerned about poor compliance with treatment and whether there are counseling treatments available.”

You Might Also Like
  • Addiction Therapy Is Underprescribed but May Benefit Medical Adherence
  • U.S. to Promote Use of Opioid Alternatives to Treat Addiction
  • U.S. FDA Approves First-Ever Implant to Treat Opioid Addiction
Also By This Author
  • Expert Says Vaccines Are Largely Safe for Rheumatology Patients

A Treatment Model
In Baltimore, Dr. Stoller is involved with an integrative approach called collaborative opioid prescribing, which encourages physicians to get waivers to prescribe buprenorphine. Comprehensive treatment in the program includes evaluation, induction and counseling. After they’re stabilized, patients are referred for medication to the program’s hubs, usually primary care physicians. During periods of instability for patients, counseling and urinalysis monitoring are increased, and the program can resume dosing medication when appropriate.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Stoller said this may be a model for a way forward.

“The thing I love about this model the most is that my patients are now motivated to go to their primary care provider appointments,” he said. “Because if they don’t, they’re not getting their prescription. And so they’re finally getting their chronic medical problems addressed.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Thomas R. Collins is a freelance writer living in South Florida.

Reference

  1. Clark R, Samnaliev M, Baxter J, et al. The evidence doesn’t justify steps by state medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff (Millwood). 2011 Aug;30(8):1425–1433.

Pages: 1 2 3 | Single Page

Filed Under: Conditions Tagged With: Addiction, addiction treatment, Opioid abuse, Opioids

You Might Also Like:
  • Addiction Therapy Is Underprescribed but May Benefit Medical Adherence
  • U.S. to Promote Use of Opioid Alternatives to Treat Addiction
  • U.S. FDA Approves First-Ever Implant to Treat Opioid Addiction
  • U.S. Lets More Healthcare Workers Prescribe Opioid Addiction Treatment

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.